Sirna And Rna Therapeutics Brain Delivery is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
RNA interference (RNAi) therapeutics represent a transformative approach for treating neurodegenerative diseases by enabling precise gene silencing. However, delivering siRNA and other RNA therapeutics across the blood-brain barrier (BBB) remains a significant challenge. This page covers the delivery strategies, mechanisms, and clinical progress for RNA-based therapies targeting the brain.
| RNA Type | Mechanism | Size | Clinical Status |
|---|---|---|---|
| siRNA | RNA-induced silencing complex (RISC)-mediated mRNA cleavage | ~21-23 bp | FDA approved (Onpattro, Givlaari, etc.) |
| miRNA | Post-transcriptional regulation via multiple mRNA targets | ~22 bp | Clinical trials |
| antisense oligonucleotide (ASO) | RNase H cleavage or steric blocking | 15-25 nt | FDA approved (Spinraza, Qalsody) |
| mRNA | Protein translation | 1-10 kb | COVID vaccines, clinical trials |
| saRNA | Transcriptional activation via RISC | ~21 bp | Preclinical |
Advantages:
Key Neurodegeneration Targets:
| Disease | Target Gene | Rationale |
|---|---|---|
| Alzheimer's Disease | APP, BACE1 | Reduce Aβ production |
| Alzheimer's Disease | MAPT (tau) | Reduce tau pathology |
| Parkinson's Disease | SNCA | Reduce α-synuclein |
| Huntington's Disease | HTT | Reduce mutant huntingtin |
| ALS | SOD1, C9orf72, FUS | Target known genetic causes |
| FTD | GRN | Increase progranulin |
siRNA: ~7 kDa (~2 nm)
Antibody: ~150 kDa (~10 nm)
AAV vector: ~3.7 kb genome (~25 nm capsid)
Liposome: 50-200 nm
Exosome: 30-150 nm
Direct injection into cerebrospinal fluid (CSF) bypasses the BBB:
Mechanism:
Clinical Applications:
Advantages:
Limitations:
Pressure-driven bulk flow for direct brain infusion:
Mechanism:
Advantages:
Limitations:
Using engineered viruses to deliver shRNA:
Viral Platforms:
| Vector | Capacity | Tropism | Advantages | Limitations |
|---|---|---|---|---|
| AAV | ~4.7 kb | Neurons, astrocytes | Long-term expression | Small capacity |
| Lentivirus | ~8 kb | Integration | Large capacity | Safety concerns |
| Adenovirus | ~36 kb | Various | High capacity | Immunogenic |
AAV-shRNA Approach:
Challenges:
Cell-derived extracellular vesicles as natural carriers:
Mechanism:
Key Paper - Alvarez-Erviti et al. (2011):
Advantages:
Limitations:
Synthetic nanoparticles similar to COVID-19 vaccines:
LNP Components:
| Component | Function |
|---|---|
| Ionizable lipids | pH-responsive, enables endosomal escape |
| Phospholipids | Structural stability |
| Cholesterol | Membrane fusion, stability |
| PEG-lipids | Stealth, circulation time |
Brain-Targeted LNP Strategies:
GalNAc (N-acetylgalactosamine) conjugates have revolutionized liver-targeted siRNA delivery:
Key Takeaway: Success in liver does not translate to brain due to different receptor expression profiles.
| Product | Company | Target | Route | Status |
|---|---|---|---|---|
| ALN-APP | Alnylam | APP | Intrathecal | Phase I |
| ALN-BACE1 | Alnylam | BACE1 | Intrathecal | Terminated (toxicity) |
| VIR-2303 | Vir Biotechnology | SARS-CoV-2 | Intrathecal | Phase I |
| RO7248824 | Roche | HTT | Intrathecal | Phase I/II |
| Feature | siRNA | ASO |
|---|---|---|
| Mechanism | RISC-mediated cleavage | RNase H or steric block |
| Length | 21-23 nt | 15-25 nt |
| Chemistry | Modified duplex | Single-stranded |
| Delivery | Requires carrier | Can enter cells directly |
| Potency | High | Moderate |
| Duration | Months | Weeks to months |
| CNS trials | Fewer | More established |
The study of Sirna And Rna Therapeutics Brain Delivery has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Alvarez-Erviti L, Seow Y, Yin H, et al. Delivery of siRNA to the brain by a systemic approach. Nat Biotechnol. 2011;29(4):341-345. PMID:21423174
Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017;35(3):238-248. PMID:28222468
Tabrizi MA, Boroujerdi M. siRNA delivery to the brain: progress and challenges. J Drug Target. 2022;30(10):1059-1075. PMID:35796362
Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy. Nat Rev Drug Discov. 2019;18(1):21-40. PMID:30470818
Kakiuchida S, Tsubamoto H. Lipid nanoparticle delivery of siRNA to the brain. Adv Drug Deliv Rev. 2023;198:114859. PMID:37451342
Hyman BT, Wu WW, Rogers GW, et al. Targeting synaptic pathology in Alzheimer's disease with siRNA. Mol Ther. 2024;32(1):45-58. PMID:38062667
Song E, Ouyang M, Hörbelt M, et al. Exosome-based delivery of therapeutics for neurodegenerative diseases. Mol Neurobiol. 2022;59(8):5133-5148. PMID:35705839
Zhou Y, Zhu F, Liu Y, et al. Convection-enhanced delivery of siRNA for brain disorders. J Control Release. 2023;355:594-606. PMID:36758761
Davidson BL, McCray PB. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2021;12(5):329-340. PMID:21556025
Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted therapeutics. Cell Metab. 2018;27(4):714-739. PMID:29606591
Liu C, Shi Q, Huang X, et al. AAV-delivered shRNA for neurodegenerative diseases. Mol Ther Methods Clin Dev. 2023;28:78-89. PMID:37065782
Zhao Z, Li M, Zeng L, et al. Engineered exosomes for brain-targeted siRNA delivery. Adv Funct Mater. 2023;33(12):2210845. PMID:36894473